Upcoming event

Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time

European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View

Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma

European Urology Oncology, October 2022

Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma

Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups

European Urology Open Science, January 2023

89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study

Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups

Phase II study of axitinib prior to partial nephrectomy to preserve renal function: An interim analysis of the PADRES clinical trial

Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial

PreviousNext